On the September 22 broadcast of Mayo Clinic Radio, Yi Lin, M.D., Ph.D., a hematologist at Mayo Clinic and Chair of the Cellular Therapeutics Cross-Disciplinary Group in the Mayo Clinic Cancer Center, explained how chimeric antigen receptor T-cell therapy (CAR T-cell therapy) works and where the research is headed.
In this new cancer treatment, cells in the immune system, known as T cells, are genetically modified to equip them to recognize and destroy cancer cells. CAR T-cell therapy was approved by the U.S. Food and Drug Administration (FDA) last year to treat two types of blood cancer—relapsed B-cell acute lymphoblastic leukemia and relapsed B-cell non-Hodgkin lymphoma. Less than 15% of people who experience recurrence of those cancers respond completely to existing treatments. Up to 90% of people respond to CAR T-cell therapy, with 40% to 50% experiencing remission.
Dr. Lin discussed how CAR T-cell therapy works, new research and developments, and which patients use CAR T-cell therapy and how they recover.
Watch the podcast interview on YouTube.